文献速递妇科

辅助铂类化疗期间抗生素与质子泵抑制剂使用对子宫内膜癌患者生存的影响

The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2023-09-21

这项回顾性单机构队列研究纳入2014至2020年接受至少四周期辅助铂类化疗的325例子宫内膜癌患者,比较抗生素与质子泵抑制剂使用与生存的关系。多变量分析显示质子泵抑制剂使用与更差的无进展生存和总生存独立相关,抗生素使用仅在单变量分析中与更差无进展生存相关。

要点

  • 质子泵抑制剂使用与更差无进展生存独立相关(HR 1.96,95% CI 1.25-3.08;p=0.0041)。
  • 质子泵抑制剂使用与更差总生存独立相关(HR 2.06,95% CI 1.01-4.18;p=0.04)。
  • 抗生素使用仅在单变量分析中与更差无进展生存相关。

核心结论

  • 在这项回顾性队列研究中,质子泵抑制剂使用与接受铂类化疗的子宫内膜癌患者更差的无进展生存和总生存独立相关。
  • 抗生素使用仅在单变量分析中与更差的无进展生存相关。
  • 尚需理解质子泵抑制剂、抗生素及潜在微生物组如何影响子宫内膜癌患者化疗疗效。

研究设计与样本

  • 回顾性单机构队列研究,纳入2014至2020年接受手术分期后至少四周期辅助铂类化疗的子宫内膜癌患者325例。
  • 使用卡方检验和Fisher精确检验比较人口学与临床病理特征(包括抗生素和质子泵抑制剂使用),采用单变量和多变量分析,生存结局用对数秩检验比较。

主要发现

  • 325例患者中,95例(29%)接受抗生素,80例(24.6%)接受质子泵抑制剂。
  • 抗生素使用与3年无进展生存降低相关(49.9% vs 66%;p=0.0237),但3年总生存无显著差异(68.9% vs 79.9%;p=0.0649)。
  • 针对革兰阳性菌的抗生素与无抗生素和其他抗生素相比,3年无进展生存降低(21.2% vs 66.0% vs 55.4%;p=0.0038),3年总生存降低(36.5% vs 79.9% vs 75.6%;p=0.0014)。
  • 质子泵抑制剂使用与无质子泵抑制剂相比,3年无进展生存降低(46.9% vs 66.0%;p=0.0001),3年总生存降低(60.7% vs 81.9%;p=0.0041)。
  • 控制分期、组织学、分级、放疗和合并症等混杂因素的多变量回归分析中,质子泵抑制剂使用与更差无进展生存独立相关(HR 1.96,95% CI 1.25-3.08;p=0.0041)和更差总生存独立相关(HR 2.06,95% CI 1.01-4.18;p=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to assess the impact of antibiotic (ABX) and proton-pump inhibitor (PPI) use on progression-free (PFS) and overall survival (OS) in patients treated with adjuvant platinum-based chemotherapy (PC) for endometrial cancer (EC). METHODS: A retrospective, single-institution cohort study of EC patients treated with ≥four cycles of adjuvant PC following surgical staging from 2014 to 2020. Demographics and clinicopathologic features, including ABX and PPI use, were compared using χ2 and Fisher's exact tests. Univariate and multivariable analyses were performed, and survival outcomes were compared using the log-rank test. RESULTS: Of 325 patients, 95 (29%) received ABX, and 80 (24.6%) received PPI. ABX were associated with decreased 3-year PFS (49.9% vs. 66%; p = 0.0237) but not 3-year OS (68.9% vs. 79.9%; p = 0.0649). ABX targeting gram-positive bacteria were associated with decreased 3-year PFS (21.2% vs. 66.0% vs. 55.4%; p = 0.0038) and 3-year OS (36.5% vs. 79.9% vs. 75.6%; p = 0.0014) compared to no ABX and other ABX, respectively. PPI use was associated with decreased 3-year PFS (46.9% vs. 66.0%; p = 0.0001) and 3-year OS (60.7% vs. 81.9%; p = 0.0041) compared to no PPI. On multivariable regression analysis controlling for confounders including stage, histology, grade, radiation, and co-morbidities, PPI use was independently associated with worse PFS (HR 1.96, 95% CI 1.25-3.08; p = 0.0041) and OS (HR 2.06, 95% CI 1.01-4.18, p = 0.04). CONCLUSION: In this retrospective cohort study, we demonstrate that PPI use is independently associated with worse PFS and OS in patients with EC treated with PC. ABX use was associated with worse PFS on univariate analysis only. There is an unmet need to understand how PPI, ABX, and, potentially, the microbiome impact the effectiveness of chemotherapy in EC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Haight PJ, Kistenfeger Q, Riedinger CJ, et al. The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer. Gynecol Oncol. 2023. PMID: 37741201. doi:10.1016/j.ygyno.2023.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。